ArticlePLoS neglected tropical diseases2025
Phenotypic dichotomy in Crotalus durissus ruruima venom and potential consequences for clinical management of snakebite envenomations.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- BrazilianToxins · 2026Article
- Snakebite Envenomations In The Brazilian Amazon: A Little Less Neglected.Revista da Sociedade Brasileira de Medicina Tropical · 2026Review
- Snake Venom PLAToxins · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundPhenotypic polymorphism in rattlesnake venoms is well-documented, with a dichotomy between hemorrhagic (Type I) and neurotoxic (Type II) venoms. In South America, the Type II phenotype is predominant; however, evidence of Type I venom in Crotalus durissus ruruima raises concerns about the efficacy of the Crotalus antivenom, which is prepared only with Type II venoms. Consequently, the Bothrops-Crotalus antivenom has been proposed as an alternative treatment for envenomation by Type I venoms. METHODOLOGY/PRINCIPAL
findingsThis study characterizes the dichotomy of C. d. ruruima venom by analyzing the structure of isoforms differentially expressed in Type I and Type II venoms, assessing their biological activities, and evaluating the implications for snakebite clinical management in Roraima State (northern Brazil). Four toxins were differentially expressed between Type I and Type II venoms: two PIII-class SVMPs, predominantly found in Type I venoms, associated with proteolytic and hemorrhagic activity; and two PLA2s, corresponding to Crotoxin A and B chains, prevalent in Type II venoms and related to elevated phospholipase A2 activity, myotoxicity, and increased lethality. The structure of Crotoxin chains was well conserved compared to C. d. terrificus Crotoxin. However, the SVMP sequences exhibited multiple substitutions in functional and immunoreactive regions compared to Bothropasin, resulting in low hemorrhagic activity and limited reactivity/neutralization by the Bothrops antivenom. Conversely, the Crotalus antivenom reacted with high antibody titer and neutralized all activities of both venom subtypes, except for the low hemorrhagic activity induced by Type I venoms. CONCLUSIONS/SIGNIFICANCE: The efficacy of Bothrops antivenom in snakebites caused by rattlesnakes with Type I venoms remains uncertain. We advocate for a clinical study in Roraima to assess patient outcomes and benefits of Bothrops-Crotalus versus Crotalus antivenoms for these accidents. Meanwhile, administering Bothrops-Crotalus antivenom may be acceptable; however, caution is needed regarding the use of heterologous Bothrops antibodies, which have limited efficacy in treating Crotalus envenomation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.